Sign in to view content

Novel Vascular Endothelial Growth-Factor A (VEGF-A) and Angiopoietin-2 (Ang-2) Bispecific Protein, RO-634, in Comparison to Aflibercept

Mark R. Barakat, MD

Video
Published 2022

Related

Additional Visual and Anatomic Outcomes of Intravitreal Aflibercept Injection, 8 mg vs 2 mg: Post Hoc Analysis of the Phase 2 CANDELA Study
Priya Sharma Vakharia, MD
Annual Meeting Talks
2023
Long-Term Outcome of Diabetic Eyes With Vitreous Hemorrhage in an Urban Safety-Net Hospital
Hossein Ameri, MD, PhD, FRCSI, MRCOphth
Annual Meeting Talks
2024
Episode 21: Eyes with PDR that were Lost to Followup after PRP or Anti-VEGF Treatment with Dr. Jason Hsu
Keyvan Koushan, MD, FRCSC
Member Podcasts
2018

Category: Pharmacology

See more